|Other Names||Ubiquitin-like modifier-activating enzyme 5, Ubiquitin-activating enzyme 5, ThiFP1, UFM1-activating enzyme, Ubiquitin-activating enzyme E1 domain-containing protein 1, UBA5, UBE1DC1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP2186a was selected from the N-term region of human Uba5. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||E1-like enzyme which activates UFM1 and SUMO2.|
|Cellular Location||Cytoplasm. Nucleus. Note=Localizes mainly in cytoplasm, while it mainly localizes to the nucleus in presence of SUMO2 (PubMed:18442052)|
|Tissue Location||Widely expressed.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Various ubiquitin-like (UBL) post-translational modifiers contribute critically to the protein degradation pathway. These UBLs are covalently linked to most target proteins through an enzymatic cascade analogous to ubiquitylation, consisting of E1 (activating), E2 (conjugating), and E3 (ligating) enzymes. Uba5 is an E1-like enzyme that belongs to the ubiquitin-activating enzyme family, and activates UFM1, a novel ubiquitin-fold modifier.
Komatsu, M., et al., EMBO J. 23(9):1977-1986 (2004).
If you have any additional inquiries please email technical services at email@example.com.